For example, a study using the TKI, imatinib, to treat chronic myelogenous leukemia (CML) patients, observed a depletion of Tregs and a significant increase in effector/memory CD8+ T cells in CML patients in complete molecular remission (CMR) compared to non-CMR patients (109). This evidence concerns the gene CD8A and chronic myelogenous leukemia, BCR-ABL1 positive.